• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

    5/7/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email

    CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City.

    Details for the presentation are as follows:

    Title: Assessment of Bezisterim (NE3107) in Patients with Early Parkinson's Disease: A Phase 2, Placebo-Controlled, Hybrid Decentralized Study

    Presentation date and time: Saturday, May 10

    Presentation time: 8:00-9:00am EDT

    Presenter: Joseph M. Palumbo, MD, Executive Vice President, Head of Research & Development and Chief Medical Officer, BioVie Inc.

    SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety follow up.

    As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committee. If the trial's results are positive, participants may be eligible to enter a longer-term, open-label safety study.

    About Parkinson's Disease        

    Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Core symptoms include tremors, muscle rigidity, bradykinesia (slowness of movement), postural instability, and difficulties with speech.1-2 Non-motor symptoms, such as cognitive impairment, mood disorders, and autonomic dysfunction, also significantly impact patients' quality of life.3 In the early stages, symptoms are often mild and may include subtle tremors, slight movement difficulties, and changes in handwriting or facial expressions. As the disease progresses, motor symptoms become more pronounced, leading to difficulties with balance, speech, and daily activities, often requiring full-time care in later stages.4

    Since the 1960s, when dopamine's critical role in Parkinson's disease was first identified, levodopa has remained the cornerstone of treatment, providing significant symptom relief by replenishing dopamine levels in the brain.5-6 However, long-term use is associated with complications such as motor fluctuations—where symptom control becomes less stable—and dyskinesia, involuntary movements that can become debilitating.7-9

    Emerging research highlights the role of chronic inflammation and insulin resistance in the onset and progression of Parkinson's disease. Neuroinflammation, driven by activated microglia and elevated levels of pro-inflammatory cytokines, contributes to oxidative stress and accelerates neuronal degeneration.10-12 Additionally, insulin resistance, which impairs the brain's ability to regulate glucose metabolism, has been linked to increased neurodegeneration and worsening motor symptoms.13-14 These metabolic dysfunctions create a harmful cycle that exacerbates disease progression, underscoring the potential of anti-inflammatory and insulin-sensitizing therapies as new avenues for treatment.

    About Bezisterim        

    Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID.

    In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events.

    In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ("brain fog") and fatigue.

    In Alzehimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease.

    About BioVie Inc.        

    BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

    Forward-Looking Statements 

    This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

    References        

    1 Cleveland Clinic. Parkinson's Disease. Last reviewed: 2022 Apr 15.

    2 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.

    3 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.

    4 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.

    5 Hornykiewicz O. Angew Chem Int Ed. 2002;41(17):2934-2941.

    6 Olanow CW, Obeso JA and Stocchi F. Lancet Neurol. 2006;5(8):677-687.

    7 Ahlskog JE and Muenter MD. Mov Disord. 2001;16(3):448-458.

    8 Espay AJ, Morgante F, Merola A, et al. Ann Neurol. 2018;84(6):797-811.

    9 Cilia R and Akpalu A. J Neural Transm. 2020;127(5):889-916.

    10 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.

    11 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.

    12 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.

    13 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.

    14 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16):3585.

    For Investor Relations Inquiries: 

    Contact: 

    Bruce Mackle 

    Managing Director 

    LifeSci Advisors, LLC 

    [email protected] 

    For Media Inquires

    Melyssa Weible

    Managing Partner, Elixir Health Public Relations 

    Ph: +1 201-723-5705

    [email protected]



    Primary Logo

    Get the next $BIVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:26:37 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:24:53 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Michael Edward

      4 - BIOVIE INC. (0001580149) (Issuer)

      1/7/25 5:21:05 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

      Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

      7/22/22 7:51:28 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on BioVie with a new price target

      B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

      11/30/21 8:23:48 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Leadership Updates

    Live Leadership Updates

    See more

    $BIVI
    SEC Filings

    See more
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

      CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

      6/4/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Announces the Appointment of a New Chief Medical Officer

      RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

      11/1/21 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by BioVie Inc.

      PRE 14A - BIOVIE INC. (0001580149) (Filer)

      5/8/25 5:20:30 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by BioVie Inc.

      PRE 14C - BIOVIE INC. (0001580149) (Filer)

      5/7/25 5:20:08 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIOVIE INC. (0001580149) (Filer)

      3/28/25 5:00:27 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Financials

    Live finance-specific insights

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

      CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

      11/20/24 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioVie Inc.

      SC 13G - BIOVIE INC. (0001580149) (Subject)

      10/25/24 4:01:25 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioVie Inc.

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      6/25/24 7:47:33 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

      SC 13D/A - BIOVIE INC. (0001580149) (Subject)

      3/10/23 5:15:43 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Do Cuong V bought 10,000 shares (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      3/6/24 5:12:41 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

      4 - BIOVIE INC. (0001580149) (Issuer)

      12/1/23 6:26:32 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care